BOARD OF DIRECTORS

Kurt Graves

Chairman, President and CEO

Mr. Graves is a global industry leader with more than twenty years of US and global general management experience in top-tier US and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies; at Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Most recently Mr. Graves served as the Executive Chairman of Intarcia Therapeutics. Prior to that Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals from 2007 through the end of 2009. Prior to his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Prior to his tenure at Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves serves as Chairman of the Board at Intarcia and Radius therapeutics and as a Director at Springleaf Therapeutics and Pulmatrix Pharmaceuticals. Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.


Bryan Roberts, Ph.D.

Director

Bryan Roberts joined Venrock, a venture capital investment firm, in 1997, where he serves as partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts is the chairman of Ironwood Pharmaceuticals and serves on the board of directors of ZELTIQ as well as on the board of several other private companies, and he has previously served on the board of directors of athenahealth, Inc., XenoPort, Inc. and Sirna Therapeutics, Inc. He received a B.A. from Dartmouth College and a Ph.D. in chemistry and chemical biology from Harvard University.


Gino Santini

Director

Gino Santini is a globally respected pharmaceutical executive, having spent nearly three decades at Eli Lilly and Company where he served in a number of key roles, including as a member of their Executive Committee. His distinguished career began when he joined Lilly as a Financial Planning Associate in Italy in 1983. He went on to serve in financial and marketing roles in Italy and Indianapolis, and also served as Pharmaceutical Director in Belgium, General Manager in Mexico City, Area Director of Latin America, President of Lilly’s women’s health business, and President of U.S. Operations, before ascending to Senior Vice President of Corporate Strategy and Business Development. In this final role, Mr. Santini led corporate strategy and long-range planning, M&A, new product licensing, innovative financing of internal development projects, and the expansion of Lilly Ventures in the U.S. and China. In addition to Intarcia, Mr. Santini serves on the Boards of Directors of several biopharmaceutical companies and an Italian financial holding company of businesses in the sugar, food, mechanical, and packaging sectors. He serves as an Associate Member of the Board of the National Association of Chain Drug Stores, and previously served as Chairman of the Board of the National Pharmaceutical Council, and as Chairman of the Board of Noble of Indiana, a non-profit agency that serves people with developmental disabilities. He is also a former Director of the United Way, and a former Member of the Executive Committee and Board of the Indianapolis Chamber of Commerce. Fluent in four languages, Mr. Santini holds an undergraduate degree in mechanical engineering from the University of Bologna and an MBA from the Simon School of Business, University of Rochester.


Glen Sato, J.D.

Director

Glen Sato has been a partner in the Life Sciences and Companies practice group at Cooley Godward LLP since January 2006. Prior to that time, he served as Senior Vice President and Chief Financial Officer of PDL BioPharma, Inc. (PDL) from May 2003 to September 2005. He joined PDL from Exelixis, Inc., where he had served as Chief Financial Officer and General Counsel since November 1999. Previous to Exelixis, he served in various legal and strategic planning positions at PDL, most recently as Vice President, Legal and General Counsel. During his tenure at PDL and Exelixis, Mr. Sato was responsible for finance, SEC reporting and compliance, disclosure issues and internal and external business functions, including business development, intellectual property licensing and licensing strategy, general corporate counseling, insider trading compliance and intellectual property protection. He received his Bachelor of Arts from Wesleyan University, and his J.D. and M.B.A. from UCLA.


Irwin Scher, M.D

Director

Irwin Scher, M.D. has served as a member of our board of directors since April 2005. Since March 2005, Dr. Scher has served as the Chief Executive Officer of Biosynexus, Incorporated, a biopharmaceutical company. From January 2002 to January 2005, Dr. Scher served as a full-time development and business consultant to the chief executive officer of Merck KgaA in Darmstadt, Germany, a global pharmaceutical products and services company, while also serving as Vice President, global clinical research and development for Merck KgaA from June 2002 to September 2003. From January 1992 to August 1999, Dr. Scher served as Senior Vice President, Drug Development and Medical Affairs at Astra/Merck, a joint venture of Astra AB and Merck, and AstraZeneca, a global pharmaceutical products company. Dr. Scher is a director of Clarient, Inc. Dr. Scher holds a B.S. in chemistry from the New York State University at Albany and an M.D. from the Albert Einstein College of Medicine. He is board certified in internal medicine and rheumatology.

Nancy Thornberry

Director

Nancy Thornberry became a member of the Intarcia Board of Directors in December 2013. She is a highly regarded expert in pharmaceutical R&D, and strategy and portfolio management. Nancy has been involved in scientific innovation in diverse areas, which paved the way for significant breakthroughs. This took place during her illustrious 34-year career at Merck Research Laboratories, where she began in 1979 as a Biochemist, and steadily assumed positions of increasing responsibility – distinguishing herself along the way with numerous and significant achievements. Those achievements came early as Nancy provided enzymology support to the angiotensin converting enzyme (ACE) inhibitor project for the treatment of hypertension, and multiple other targets. Her accomplishments also include the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1), and contributions to the discovery of the target of ezetimibe, the active ingredient in ZETIA™. Most notably, she co-led the team that discovered Januvia™ (sitagliptin) in 2001, which is currently the #1 branded oral agent for the treatment of type 2 diabetes, and the largest selling product in Merck history. In 2011 Nancy became SVP and Franchise Head of Diabetes and Endocrinology for Merck Research Laboratories. Also in 2011 Nancy was honored with the PhRMA Discoverers Award. In addition to her prolific publishing record, Nancy has guest lectured at prestigious venues, as well as chaired many key scientific and medical sessions.

 

Our Strategy

At Intarcia, our goal is to develop and commercialize drug therapies that deliver an improved therapeutic outcome while enhancing patients' quality of life.


LEARN MORE